UTHR
UNITED THERAPEUTICS Corp
NASDAQ · Healthcare · Biotechnology · US
$593.54
+1.20%Oct 23, 2026, 17:30 UTC
UNITED THERAPEUTICS Corp plans to begin construction in early 2027 on a $9 million, 27,000- to 33,000-square-foot corporate airplane hangar near Rochester International Airport, with completion expected in 2028.
Source:Oct 22, 2026, 11:00 UTC
UNITED THERAPEUTICS Corp announced that its board authorized a share repurchase program of up to $2 billion in common stock, available through October 21, 2027.
Source:Oct 21, 2026, 11:00 UTC
United Therapeutics announced that it will release its third-quarter 2026 financial results and host a public webcast on November 4, 2026.
Source:Oct 20, 2026, 11:00 UTC
United Therapeutics announced the opening of its third designated pathogen-free xenograft production facility in Houston, Texas.
Source:Oct 14, 2026, 14:00 UTC
Liquidia agreed to terminate its promotional agreement for treprostinil injection and stop supporting sales of the product in the market.
Source:Oct 13, 2026, 21:44 UTC
Liquidia Corp entered into a global settlement agreement with UNITED THERAPEUTICS Corp, resolving all pending litigation between the companies.
Oct 1, 2026, 17:20 UTC
United Therapeutics prevailed in its patent dispute with Liquidia over the Yutrepia product, a ruling that could limit Yutrepia's use in PH-ILD and reduce competition for United Therapeutics' Tyvaso products.
Oct 1, 2026, 12:05 UTC
United Therapeutics (UTHR) shares rose 12.6% in the previous trading session on higher-than-average volume.
Source:Sep 30, 2026, 17:20 UTC
The U.S. District Court for the District of Delaware ruled that two of the six patent claims asserted by United Therapeutics against Liquidia are valid and infringed, and directed the parties to submit a proposed form of judgment within one week.
Sep 27, 2026, 01:46 UTC
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp., sold 9,500 shares of the company's common stock on September 22, 2026, for a total of $4,700,850 under a pre-arranged 10b5-1 trading plan.
Source:Sep 24, 2026, 11:45 UTC
United Therapeutics Corporation is sponsoring the EXPAND study, the world's first clinical trial of gene-edited pig kidney xenotransplantation for people with end-stage kidney disease, with the first patient receiving a modified kidney at NYU Langone Health in November 2025.
Source:Sep 8, 2026, 11:00 UTC
United Therapeutics announced it will enter into an accelerated share repurchase agreement with Citibank to repurchase approximately $477.6 million of its common stock, completing the remainder of its $2.0 billion share repurchase authorization.
Source:Sep 2, 2026, 11:00 UTC
United Therapeutics announced that the FDA accepted its supplemental New Drug Application for nebulized Tyvaso (treprostinil) Inhalation Solution to treat idiopathic pulmonary fibrosis, with review expected to complete in late April 2027.
Source:Aug 24, 2026, 11:00 UTC
United Therapeutics Corporation announced that the FDA has accepted its New Drug Application for ralinepag to treat pulmonary arterial hypertension, with a target action date of June 24, 2027.
Aug 18, 2026, 15:41 UTC
United Therapeutics completed enrollment in its Phase III study evaluating Tyvaso for an additional indication, progressive pulmonary fibrosis (PPF), with top-line results expected in the second half of 2027.
Source:Aug 11, 2026, 08:09 UTC
United Therapeutics CEO Martine Rothblatt sold 9,500 shares of the company's stock on August 7, 2026, at an average price of $531.38, totaling about $5.05 million.
Source:Aug 5, 2026, 10:30 UTC
United Therapeutics Corporation reported its financial results for the second quarter of 2026, with total revenues decreasing by two percent year-over-year to $783.3 million from $798.6 million in the same quarter of 2025.
Jul 23, 2026, 00:00 UTC
United Therapeutics Corp appointed Victor Dzau, M.D. as a member of its Board of Directors, effective July 22, 2026.